N-(3-methylphenyl)piperidin-4-amine | 1178145-01-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-(3-methylphenyl)piperidin-4-amine
• CAS: 1178145-01-1
• 化学式: C₁₂H₁₈N₂
• mdl: MFCD12822073
• 分子量: 190.28
• InChiKey: JGBUGLFDHDBOOV-UHFFFAOYSA-N

物化性质

• 沸点：
  329.0±35.0 °C(Predicted)
• 密度：
  1.035±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  24.1
• 氢给体数：
  2
• 氢受体数：
  2

文献信息

• [EN] PRMT5 INHIBITORS AND USES THEREOF<br/>[FR] INHIBITEURS DE PRMT5 ET LEURS UTILISATIONS
  申请人：EPIZYME INC

  公开号：WO2014100734A1

  公开（公告）日：2014-06-26

  Described herein are compounds of formula (A), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting PRMT5 activity. Methods of using the compounds for treating PRMT5-mediated disorders are also described.

  本文描述了式（A）的化合物，其药学上可接受的盐以及药物组成物。本发明的化合物对抑制PRMT5活性是有用的。还描述了利用这些化合物治疗PRMT5介导的疾病的方法。
• Dihydrothienopyrimidines for the Treatment of Inflammatory Diseases
  申请人：Pouzet Pascale

  公开号：US20080096882A1

  公开（公告）日：2008-04-24

  The invention relates to new dihydrothienopyrimidine of formula 1, as well as pharmacologically acceptable salts, diastereomers, enantiomers, racemates, hydrates or solvates thereof, wherein X is SO or SO 2 , but preferably SO, and wherein R 1 , R 2 and R 3 have the meanings given in the description, and which are suitable for the treatment of respiratory or gastrointestinal complaints or diseases, inflammatory diseases of the joints, skin or eyes, diseases of the peripheral or central nervous system or cancers, as well as pharmaceutical compositions which contain these compounds.

  该发明涉及公式1的新二氢噻吡嘧啶，以及其药理学上可接受的盐、对映体、旋光异构体、消旋体、水合物或溶剂合物，其中X为SO或SO2，但最好为SO，R1、R2和R3在描述中给出的含义，并且适用于治疗呼吸道或胃肠道疾病、关节、皮肤或眼睛的炎症性疾病、外周或中枢神经系统疾病或癌症，以及含有这些化合物的药物组合物。
• PREPARATION OF DIHYDROTHIENO [3, 2-D] PYRIMIDINES AND INTERMEDIATES USED THEREIN
  申请人：Frutos Rogelio

  公开号：US20100222585A1

  公开（公告）日：2010-09-02

  The invention relates to improved methods of preparing dihydrothienopyrimidines of formula 1, and intermediates thereof, (I) wherein X is SO or SO 2 , preferably SO, and wherein R A , R 1 , R 2 , R 3 , R 4 and R 5 have the meanings given in the description. The methods according to this invention are more suitable for large-scale synthesis of said pounds than prior methods because the new synthetic process avoids distillation and chromatographic purification between steps and results in a higher overall yield of the desired product.

  本发明涉及改进的制备式1的二氢噻唑嘧啶化合物及其中间体的方法，其中X为SO或SO2，优选为SO，RA、R1、R2、R3、R4和R5具有所述描述中给出的含义。本发明的方法比先前的方法更适用于大规模合成所述化合物，因为新的合成过程避免了蒸馏和色谱纯化步骤，从而得到所需产物的总收率更高。
• PRMT5 INHIBITORS AND USES THEREOF
  申请人：Epizyme, Inc.

  公开号：US20140329794A1

  公开（公告）日：2014-11-06

  Described herein are compounds of Formula (I), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting PRMT5 activity. Methods of using the compounds for treating PRMT5-mediated disorders are also described.

  本文描述了公式（I）的化合物，其药学上可接受的盐以及其制药组合物。本发明的化合物可用于抑制PRMT5活性。还描述了使用这些化合物治疗PRMT5介导的疾病的方法。
• TETRAHYDRO- AND DIHYDRO-ISOQUINOLINE PRMT5 INHIBITORS AND USES THEREOF
  申请人：EPIZYME, INC.

  公开号：US20150344434A1

  公开（公告）日：2015-12-03

  Described herein are compounds of Formula (A), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting PRMT5 activity. Methods of using the compounds for treating PRMT5 mediated disorders are also described.

  本文描述了公式（A）的化合物，其药学上可接受的盐以及它们的药物组合物。本发明的化合物对于抑制PRMT5活性是有用的。还描述了使用这些化合物治疗PRMT5介导的疾病的方法。